According to Kommersant, last year pharmacies sold these drugs for 3.5 billion rubles - 11% of the annual sales of all insulins in the country. At the beginning of 2022, Roszdravnadzor identified the risks of a defect in such drugs due to pricing. Geropharm, Medsintez and the Danish Novo Nordisk asked to increase the marginal prices.
The FAS clarified that the prices had to be re-registered due to an increase in production costs. An analysis is also carried out for one of the dosages of insulin glargine. Geropharm Group is already preparing to re-register the prices of most insulin positions. According to General Director Petr Rodionov, the rise in price is expected within 3-4%. For insulin aspart Novo Nordisk, the cap price has remained unchanged since 2016. For Russian drugs for which re-registration has already been agreed, from 2019-2021.
Basically, the rise in price will affect insulin in syringe pens. X the maximum cost will be higher than that of drugs in cartridges or folacons. Syringe pens are an expensive form of release, it refers to the foreign exchange component of the cost.
It should be noted that in the past, Russian manufacturers occupied 23.6% of the insulin market in monetary terms. According to experts, the rise in price will not have a serious impact on sales.
In March, it became known that foreign manufacturers of insulin would not limit the supply of the drug to Russia. The Ministry of Health stressed that the issues of drug provision are under the continuous control of the relevant departments and are a priority. The department noted the absence of problems with the production and supply of Russian insulins.